La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Teva Pharmaceutical Industries Gestion
Gestion contrôle des critères 2/4
Le PDG Teva Pharmaceutical Industries' est Richard Francis, nommé en Jan2023, a un mandat de 1.58 ans. La rémunération annuelle totale est $ 25.71M, composée du salaire de 6.2% et des bonus 93.8%, y compris les actions et options de la société. détient directement 0.011% des actions de la société, d'une valeur de $ 2.25M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 2.4 ans et 7.1 ans.
Informations clés
Richard Francis
Directeur général
US$25.7m
Rémunération totale
| Pourcentage du salaire du PDG | 6.2% |
| Durée du mandat du directeur général | 1.6yrs |
| Propriété du PDG | 0.01% |
| Durée moyenne d'occupation des postes de direction | 2.4yrs |
| Durée moyenne du mandat des membres du conseil d'administration | 7.1yrs |
Mises à jour récentes de la gestion
Recent updates
Teva's Transformation: From Generics Leader To Branded Drug Innovator
Aug 14Teva Pharmaceutical Industries Limited (NYSE:TEVA) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year
Aug 02
Teva's Q2 Outlook: Key Developments In Biosimilars And Pipeline Drugs
Jul 26Is Teva Pharmaceutical Industries (NYSE:TEVA) A Risky Investment?
Jul 12Teva Pharmaceutical: Buy This Bargain Before It's Gone
Jun 07Teva Pharmaceutical Industries Limited (NYSE:TEVA) Stock Catapults 27% Though Its Price And Business Still Lag The Industry
May 14Teva: Sustained Revenue Growth Amid Financial Strain (Rating Downgrade)
May 09Teva Pharmaceutical Industries (NYSE:TEVA) Has A Somewhat Strained Balance Sheet
Mar 26Teva Pharmaceutical Industries: Potential Outweighs Concerns
Mar 25Teva And Alvotech: Simlandi Approval Opens New Generic Market Opportunities
Feb 26A Review Of Teva's Prospects
Feb 15Teva Pharmaceutical Industries Limited's (NYSE:TEVA) Business And Shares Still Trailing The Industry
Jan 07These 4 Measures Indicate That Teva Pharmaceutical Industries (NYSE:TEVA) Is Using Debt In A Risky Way
Dec 11Teva: 4 Key Drivers For A 2024 Revival (Upgraded Rating)
Dec 08Teva: Deeply Undervalued FCF Machine
Nov 20Teva: Focus On Innovation And Growth Means The Times They Are A Changing
Sep 14Teva Pharmaceutical Industries (NYSE:TEVA) Has No Shortage Of Debt
Sep 09The Mighty Teva Pharmaceutical: Unveiling A Bullish Scenario You Must Consider
Aug 26Teva Q2 Earnings: Austedo And Anda Growth Impress, But Challenges Remain
Aug 02Teva Pharmaceutical: Lacking Capabilities For Strategic Investments
Jul 20Teva Pharmaceutical: New Growth Plan Could Restore Investor Confidence
Jun 15Here's Why Teva Pharmaceutical Industries (NYSE:TEVA) Is Weighed Down By Its Debt Load
Jun 06Is Teva Pharmaceutical Industries (NYSE:TEVA) A Risky Investment?
Feb 20What To Expect From Teva Pharmaceutical In 2023 With A New CEO
Feb 15Can Teva Pharmaceutical's Q4 results bring positive surprise?
Feb 07Teva Pharmaceutical: Stuck In A Cycle Of Hope And Disappointment
Jan 19Tamiflu supplies released from national stockpile as nationwide shortage persists
Jan 12Teva Pharmaceutical: 2023 Could Finally Be The Stock's Breakout Year
Dec 28Federal appeals court temporarily blocks generics of Vanda's Hetlioz by Teva, Apotex
Dec 16Boston jury orders Lilly to pay $176.5M to Teva in migraine drug patent suit
Nov 10Teva Pharmaceutical to pay New York $523M as part of opioid settlement
Nov 03Teva data indicates long-term benefit of Austedo for chorea associated with Huntington's
Oct 18Novartis division Sandoz reports supply issue of generic ADHD drug Adderall - Bloomberg
Oct 06Teva Pharmaceutical: Slow And Steady Road To A Higher Share Price
Sep 28Teva Pharmaceutical: Past Behind And A Promising 2023
Sep 16Analyse de la rémunération des PDG
| Date | Rémunération totale | Salaire | Bénéfices de l'entreprise |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$453m |
| Mar 31 2024 | n/a | n/a | -US$478m |
| Dec 31 2023 | US$26m | US$2m | -US$559m |
Rémunération vs marché: La rémunération totale de Richard ($USD 25.71M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché US ($USD 13.21M ).
Rémunération et revenus: Données insuffisantes pour comparer la rémunération de Richard avec les performances de l'entreprise.
PDG
Richard Francis (56 yo)
1.6yrs
Titularisation
US$25,706,880
Compensation
Mr. Richard D. Francis serves as President and Chief Executive Officer at Teva Pharmaceutical Industries Limited since January 01, 2022 and serves as its Director. Mr. Francis served as Division Head and C...
Équipe de direction
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| President | 1.6yrs | US$25.71m | 0.011% $ 2.3m | |
| Executive VP & CFO | 4.7yrs | US$4.94m | 0.064% $ 13.4m | |
| Executive Vice President of International Markets Commercial | 3yrs | US$3.73m | 0.028% $ 5.9m | |
| Executive Vice President of European Commercial | 6.8yrs | US$5.16m | 0% $ 0 | |
| Executive Vice President of Global Operations | less than a year | pas de données | pas de données | |
| Senior VP & Chief Accounting Officer | 2.8yrs | pas de données | 0.00046% $ 96.7k | |
| Head of Investor Relations | no data | pas de données | pas de données | |
| Senior Vice President | 2.1yrs | pas de données | pas de données | |
| Executive VP & Chief Legal Officer | less than a year | pas de données | pas de données | |
| Acting Head of Global Human Resources | less than a year | pas de données | 0% $ 0 | |
| Senior Vice President of Investor Relations | no data | pas de données | pas de données | |
| Senior VP & Chief Internal Auditor | 10.3yrs | pas de données | pas de données |
2.4yrs
Durée moyenne de l'emploi
52.5yo
Âge moyen
Gestion expérimentée: L'équipe de direction de TEVA est considérée comme expérimentée (ancienneté moyenne 2.4 ans).
Membres du conseil d'administration
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| President | no data | US$25.71m | 0.011% $ 2.3m | |
| Independent Chairman of the Board | 9.6yrs | US$539.99k | 0.036% $ 7.6m | |
| Independent Director | 15.6yrs | US$340.00k | 0.18% $ 38.9m | |
| Independent Director | 8.9yrs | US$355.00k | 0.0094% $ 2.0m | |
| Independent Director | 7.1yrs | US$340.00k | 0.0084% $ 1.8m | |
| Independent Director | 8.9yrs | US$330.00k | 0.0092% $ 1.9m | |
| Independent Director | 4.2yrs | US$325.46k | 0.0056% $ 1.2m | |
| Independent Director | 2.8yrs | US$330.00k | 0.0043% $ 912.6k | |
| Independent Director | 7.1yrs | US$327.87k | 0.0084% $ 1.8m | |
| Independent Director | 6.2yrs | US$315.25k | 0.0078% $ 1.6m | |
| Independent Director | less than a year | US$176.66k | pas de données |
7.1yrs
Durée moyenne de l'emploi
64yo
Âge moyen
Conseil d'administration expérimenté: Les membres du conseil d'administration de TEVA sont considérés comme expérimentés (ancienneté moyenne 7.1 ans).